Could a spring-powered injector make cancer drug delivery smoother for patients and nurses?
NCT ID NCT07721350
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This trial tests whether a mechanical, spring-driven device called FreedomEDGE® can safely and effectively deliver daratumumab, a standard treatment for multiple myeloma and amyloidosis. Currently, nurses give these injections by hand, which can be physically demanding. About 100 patients will receive one injection using the device during a routine visit. The study will measure whether the full dose is delivered without problems, how long it takes, and how patients and nurses feel about the experience.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daratumumab delivered via a spring-powered mechanical infusion system called FreedomEDGE®
- What this could lead to
- If successful, this device could make daratumumab injections more consistent and comfortable for patients, while easing the physical strain on nurses who give these injections repeatedly.
- What could go wrong
- This is a small, early-stage study focused on feasibility and safety. The device may malfunction, cause injection-site reactions, or not deliver the full dose reliably.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIGHT CHAIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Lyon-Sud
Pierre-Bénite, 69495, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.